Ascendis Pharma A/S

15 de set. de 2026, 23:41 UTC

Ascendis Pharma A/S shares are lower in after-market trading, reflecting broader market sentiment after the New York Empire State Manufacturing Index fell sharply in September.

14 de set. de 2026, 22:11 UTC

Ascendis Pharma A/S announced a $400 million share repurchase program and regained rights to develop TransCon technology products, boosting shares in after-market trading.

11 de set. de 2026, 19:46 UTC

Ascendis Pharma A/S shares are higher today, remaining above their 20-day moving average amid a broader market backdrop of CPI data aligning with expectations.

10 de set. de 2026, 20:07 UTC

Ascendis Pharma shares are rising following positive Week 52 data from its reACHin Trial, showing significant growth benefits for infants with achondroplasia.

9 de set. de 2026, 20:02 UTC

Shares of Ascendis Pharma A/S are trading lower amid a broader market decline, reflecting a notable shift in momentum since Tuesday's close.

8 de set. de 2026, 20:07 UTC

Ascendis Pharma shares are lower despite news of upcoming data presentation on TransCon CNP. Wedbush maintains an Outperform rating with a $327 price target.

2 de set. de 2026, 20:08 UTC

Oppenheimer raised its price target on Ascendis Pharma A/S to $312, contributing to the stock's upward movement during Wednesday's session.

1 de set. de 2026, 20:09 UTC

Shares of Ascendis Pharma A/S are lower today following Morgan Stanley's price target cut to $273.00, despite Wedbush's higher target of $327.00.

31 de ago. de 2026, 20:01 UTC

Ascendis Pharma shares are higher after announcing a global settlement with BioMarin, allowing continued development of navepegritide products without litigation restrictions.

25 de ago. de 2026, 20:07 UTC

Ascendis Pharma A/S shares are higher today amid a broader market rally, influenced by falling oil prices and lower Treasury yields.

24 de ago. de 2026, 19:26 UTC

Shares of Ascendis Pharma A/S are lower today, continuing a downward trend amid broader market volatility linked to geopolitical tensions involving Iran and economic sanctions.

21 de ago. de 2026, 20:01 UTC

Ascendis Pharma A/S shares are lower in Friday's session, with no specific news identified. The stock remains within its one-month range and above its 20-day moving average.

20 de ago. de 2026, 19:36 UTC

Ascendis Pharma A/S shares are lower today after a brief early peak. The stock has settled below its mid-morning low amid no specific news.

19 de ago. de 2026, 20:01 UTC

BMO Capital initiated coverage on Ascendis Pharma with an Outperform rating and a $319 price target, contributing to shares' positive movement during the session.

18 de ago. de 2026, 20:13 UTC

Ascendis Pharma A/S shares are higher in after-market trading, maintaining a steady position since Tuesday's close amid rising Treasury yields and geopolitical concerns.

17 de ago. de 2026, 19:46 UTC

Ascendis Pharma A/S shares are lower today, trading below their 20-day moving average and near the lower end of their one-month range.

14 de ago. de 2026, 21:01 UTC

Ascendis Pharma A/S shares are lower in after-market hours, amid broader market pressure from disappointing U.S. retail sales data and rising inflation concerns.

13 de ago. de 2026, 19:51 UTC

Ascendis Pharma reported strong second-quarter results, with revenue of €339 million. Shares are lower amid market volatility and profit-taking following the earnings announcement.

12 de ago. de 2026, 19:56 UTC

Ascendis Pharma A/S shares are advancing, supported by a stable market backdrop. The stock rebounded after earlier lows, reflecting positive sentiment.

11 de ago. de 2026, 20:13 UTC

Ascendis Pharma A/S shares are higher in after-market trading, remaining stable since Tuesday's close and positioned above their 20-day moving average.

10 de ago. de 2026, 19:32 UTC

Ascendis Pharma A/S shares are declining today, having pulled back from an earlier session high. The stock has traded lower since Friday's close.

7 de ago. de 2026, 19:36 UTC

Ascendis Pharma shares are higher as market sentiment improves following a weaker jobs report, suggesting a potential pause in Federal Reserve interest rate hikes.

6 de ago. de 2026, 20:06 UTC

Ascendis Pharma is trading higher after reporting significant findings from its Week 78 COACH trial, showing tripled height Z-score efficacy in children with achondroplasia.

4 de ago. de 2026, 19:36 UTC

Ascendis Pharma A/S is trading higher today, supported by positive market momentum despite recent negative economic data on U.S. core factory orders.

31 de jul. de 2026, 19:46 UTC

Ascendis Pharma A/S shares are lower today, trading significantly below their 20-day moving average amid broader market pressures from rising yields and inflation concerns.

30 de jul. de 2026, 19:09 UTC

Ascendis Pharma A/S shares are lower, continuing a decline since Wednesday. The stock is near the lower end of its one-month range.

28 de jul. de 2026, 20:01 UTC

Ascendis Pharma A/S shares are higher as the Biotechnology sub-sector advances. No specific company news was identified to explain today's price movement.

24 de jul. de 2026, 17:46 UTC

Morgan Stanley raised its price target for Ascendis Pharma to $275, maintaining an Overweight rating as shares trade higher during Friday's session.

22 de jul. de 2026, 18:36 UTC

Ascendis Pharma A/S shares are lower amid broader market sentiment affected by rising crude oil prices. The stock remains below its 20-day moving average.

21 de jul. de 2026, 20:12 UTC

Ascendis Pharma A/S shares are higher in after-market trading, supported by positive sentiment from strong earnings reports from companies like 3M and General Motors.